CA2222280A1 - Chemokine humaine beta-11 et chemokine humaine alpha-1 - Google Patents

Chemokine humaine beta-11 et chemokine humaine alpha-1 Download PDF

Info

Publication number
CA2222280A1
CA2222280A1 CA002222280A CA2222280A CA2222280A1 CA 2222280 A1 CA2222280 A1 CA 2222280A1 CA 002222280 A CA002222280 A CA 002222280A CA 2222280 A CA2222280 A CA 2222280A CA 2222280 A1 CA2222280 A1 CA 2222280A1
Authority
CA
Canada
Prior art keywords
polypeptide
polynucleotide
polypeptides
seq
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002222280A
Other languages
English (en)
Inventor
Haodong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2222280A1 publication Critical patent/CA2222280A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cette invention se rapporte à des polypeptides de chémokine humaine et à des ADN (ARN) codant ces polypeptides de chémokine, ainsi qu'à une procédure pour produire ces polypeptides par des techniques de recombinaison. Cette invention concerne également des procédés d'utilisation de ces polypeptides de chémokine dans le traitement de la leucémie, des tumeurs, des infections chroniques, des maladies auto-immunes, des troubles fibrotiques, des blessures nécessitant une cicatrisation et du psoriasis. Des antagonistes contre ces polypeptides de chémokine et leur utilisation comme agent thérapeutique pour traiter l'arthrite rhumatoïde, les maladies infectieuses et inflammatoires aiguës et chroniques et auto-immunes, les réactions allergiques, la fièvre indépendante des prostaglandines et l'insuffisance médullaire sont également décrits. Sont en outre décrites des méthodes de dosage diagnostique pour détecter les maladies apparentées à des mutations dans les séquences nucléotidiques et l'altération des concentrations de ces polypeptides. Cette invention concerne également des méthodes de dosage diagnostique pour détecter des mutations dans les polynucléotides codant ces polypeptides de chémokine et pour détecter l'altération des niveaux de ces polypeptides chez un sujet hôte.
CA002222280A 1995-06-05 1996-06-05 Chemokine humaine beta-11 et chemokine humaine alpha-1 Abandoned CA2222280A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46098795A 1995-06-05 1995-06-05
US46440195A 1995-06-05 1995-06-05
US08/460,987 1995-06-05
US08/464,401 1995-06-05

Publications (1)

Publication Number Publication Date
CA2222280A1 true CA2222280A1 (fr) 1996-12-12

Family

ID=27039874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002222280A Abandoned CA2222280A1 (fr) 1995-06-05 1996-06-05 Chemokine humaine beta-11 et chemokine humaine alpha-1

Country Status (7)

Country Link
EP (1) EP0833914A4 (fr)
JP (1) JPH11507224A (fr)
KR (1) KR19990022283A (fr)
CN (1) CN1190991A (fr)
AU (1) AU723891B2 (fr)
CA (1) CA2222280A1 (fr)
WO (1) WO1996039522A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US5633149A (en) * 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6139832A (en) * 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
AU750982B2 (en) * 1995-06-05 2002-08-01 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
WO1998011226A2 (fr) * 1996-09-10 1998-03-19 Schering Corporation Chemokines de mammiferes et reactifs apparentes
EP0950066A1 (fr) * 1996-10-04 1999-10-20 Human Genome Sciences, Inc. COMPOSITIONS ET PROCEDES THERAPEUTIQUES DE TRAITEMENT D'ETATS PATHOLOGIQUES PAR INHIBITEUR D'ADHESION LEUCOCYTAIRE-1 (LAI-1) ET PAR CHEMOKINE BETA-11(Ck$g(b)-11)
WO1998026071A1 (fr) * 1996-12-13 1998-06-18 Shionogi & Co., Ltd. Chemokine cc humaine elc
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
EP1042674A4 (fr) * 1997-10-24 2005-03-23 Human Genome Sciences Inc 148 proteines humaines secretees
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
US6110695A (en) * 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
CA2484121A1 (fr) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Anticorps a liaison specifique avec la chimiokine beta-4 (ck-b4)
CA2501422C (fr) 2004-04-29 2014-08-12 University Of Rochester Chimiokines lymphoides dans le diagnostic, la surveillance et le traitement de maladies auto-immunes
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
BR112013005145B1 (pt) 2010-09-02 2022-02-15 Vaccinex, Inc Anticorpo isolado ou seu fragmento de ligação ao antígeno que se liga especificamente ao cxcl13, composição e uso de uma composição
AU2011329647B2 (en) 2010-11-19 2015-10-22 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies
US9890213B2 (en) 2012-03-02 2018-02-13 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
JP6363623B2 (ja) 2013-01-31 2018-07-25 ヴァクシネックス， インコーポレイテッド 免疫グロブリンａのレベルを増大するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5605817A (en) * 1995-01-19 1997-02-25 Incyte Pharmaceuticals, Inc. DNA encoding chemokine expressed in fetal spleen
AU1916795A (en) * 1995-02-08 1996-08-27 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1

Also Published As

Publication number Publication date
AU723891B2 (en) 2000-09-07
AU6162896A (en) 1996-12-24
KR19990022283A (ko) 1999-03-25
EP0833914A4 (fr) 2003-05-28
CN1190991A (zh) 1998-08-19
EP0833914A1 (fr) 1998-04-08
JPH11507224A (ja) 1999-06-29
WO1996039522A1 (fr) 1996-12-12

Similar Documents

Publication Publication Date Title
AU723891B2 (en) Human chemokine beta-11 and human chemokine alpha-1
US6458349B1 (en) Chemokine β-4 polypeptides
AU708903B2 (en) Human chemokine polypeptides
EP0832233B1 (fr) Chemokine beta-13 humaine
EP0799311B1 (fr) Chemokine beta 9 humaine
MXPA97008528A (en) Chemiosine bata-13 hum
EP0811059A1 (fr) Chemokine humaine beta-11 et chemokine humaine alpha-1
US5981230A (en) Polynucleotide encoding chemokine β-4
WO1996039520A1 (fr) Chemokine beta-12 humaine
US5866373A (en) Polynucleotide encoding a human chemotactic protein
US6537539B2 (en) Immune cell cytokine
US6908986B2 (en) Chemokine alpha 3
AU750982B2 (en) Human chemokine beta-11 and human chemokine alpha-1
AU753730B2 (en) Human chemokine beta-13
EP1006188B1 (fr) Polypeptides de type chemokine humaine
US5962268A (en) DNA encoding an immune cell cytokine
US7393943B1 (en) Polynucleotides encoding a human chemotactic cytokine I
AU753088B2 (en) Human chemokine polypeptides
US20060073573A1 (en) Chemotactic cytokine III
MXPA97009090A (en) Beta-11 human chemistry and chemisine alpha-1 hum
CA2217216A1 (fr) Chemokine beta-13 humaine
EP0886642A1 (fr) Cytokine de cellule immunitaire
JP2003093076A (ja) ヒトケモカインβ−１３
WO1997023640A1 (fr) Cytokine i chimiotactique de l'homme

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead